The extent of PAK6 up-regulation inversely correlated with degree of miR-23a down-regulation (R2 = 0.69, P < 0.05) (Figure 4E), suggesting that the inhibitory effects of miR-23a on PAK6 were clinically relevant in prostate cancer. The gene discussed is PAK6; the disease is prostate carcinoma.